Global CannaVigilance Cannabis Newsletter 2023/15

Hello friends of CannaVigilance,

In the midst of fires and floods, cold spells and heatwaves, there is something to be said for indoor growing. This of course is said tongue-in-cheek as the conversation about the options continue to separate certain parts of the world from others. It’s been a busy week, especially for those with school children who are now hanging around at home. We sympathise. Let’s see what else happened this week.

Mastering Cannabis Cultivation: Insights & Certifications

Don't miss out on our latest articles, where you can become an expert in the field of cannabis cultivation. Learn why additives matter and how to navigate their impact for substantial yields. Discover the value of GMP certification in the evolving cannabis industry and explore options to upgrade product quality. Plus, delve into the significance of the Certificate of Analysis (COA) for credibility and compliance. Stay updated and gain invaluable insights from industry experts.

Our latest article on COA here.

Reconnect with Us at Upcoming Events!

Cannavigia is excited to participate in the 2023 Australian Medicinal Cannabis Symposium, held at the Brisbane Convention and Exhibition Centre from 11-13 August 2023. The event's theme, "Harnessing Knowledge, Building Momentum," embodies the excitement and progress in the medicinal cannabis industry. With experts from around the world and Australia, the symposium will explore advancements in research, improved healthcare awareness, reduced stigma, and better patient access. We are proud to sponsor and host the networking lounge this year and look forward to engaging with a fresh audience.

Learn more about our involvement and future events here.

EMCDDA: Unveiling Cannabis insights in the EU

Amidst the rapidly transforming global cannabis landscape, insightful data on legalisation is here! The EMCDDA's latest "Cannabis Laws Report" offers eye-opening statistics. This is an opportunity to discover diverse policy responses and varying cannabis use rates across Europe, including 27% of EU adults trying cannabis and 20% of the 15–24 age group using it within a year. These findings highlight challenges for public health and criminal justice systems. Stay tuned for the next one, we will be looking at their reports on seizures, price and potency. This data is crucial to pave the way for evidence-based drug policy decisions.

Stay informed on key data by keeping up with us on our LinkedIn.

A vigilant eye on cannabis news

• Ghana has become the latest African country to pass a law that allows for the cultivation of medical and industrial cannabis. The law has restrictions on THC content and comes after the interference of the Supreme Court.
• Ukraine's parliament has approved the draft law on legalising medical cannabis. To become law, it must be adopted in the second reading and then signed by the president.
• Germany’s draft law for cannabis legalisation has been hammered by industry stakeholders and would-be associations. It has been described as “impractical, contradictory in themselves, and leaning towards over-regulation.”
• Increasing pressure is being put on the South African government by lobby groups to get their ducks in a row about cannabis. This follows a request for a moratorium on arrests for possession.
  (You can read an interview about the state of the process in South Africa here)
• Questions are being asked about Portugal’s road to legislation and what the road map is. A vast majority of political parties support the move, but somehow there is no progress.
• After recent positive moves, cannaphobia has hit Brazil with the rightwing press playing a huge role in spreading disinformation. By utilising anti-vape propaganda they are aiming to block access to other sources of regulated cannabis products because democratisation would threaten the profits of the pharmaceutical cannabis industry.